Geovax Labs Inc’s recent filing unveils that its Chief Medical Officer McKee Kelly T. Jr. acquired Company’s shares for reported $742.0 on Aug 07 ’25. In the deal valued at $0.67 per share,1,107 shares were bought. As a result of this transaction, McKee Kelly T. Jr. now holds 3,494 shares worth roughly $1956.64.
Then, SPENCER JOHN N JR bought 10,000 shares, generating $9,800 in total proceeds. Upon buying the shares at $0.98, the Director now owns 11,402 shares.
Before that, Sharkey John W. bought 6,000 shares. Geovax Labs Inc shares valued at $5,940 were divested by the VP, Business Development at a price of $0.99 per share. As a result of the transaction, Sharkey John W. now holds 6,191 shares, worth roughly $3466.9600000000005.
D. Boral Capital reiterated its Geovax Labs Inc [GOVX] rating to a Buy in a research note published on April 15, 2025; the price target was $14. A number of analysts have revised their coverage, including Alliance Global Partners’s analysts, who remained covering the stock and in mid April has reiterated a ‘”a Buy”‘ rating for it. Alliance Global Partners began covering GOVX with “Buy” recommendation on November 11, 2024. ROTH MKM started covering the stock on July 16, 2024. It rated GOVX as “a Buy”.
Price Performance Review of GOVX
On Monday, Geovax Labs Inc [NASDAQ:GOVX] saw its stock jump 0.09% to $0.56. Over the last five days, the stock has lost -3.30%. Geovax Labs Inc shares have fallen nearly -75.07% since the year began. Nevertheless, the stocks have fallen -77.49% over the past one year.
How much short interest is there in Geovax Labs Inc?
A steep rise in short interest was recorded in Geovax Labs Inc stocks on 2025-09-30, dropping by -0.37 million shares to a total of 3.7 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 4.07 million shares. There was a decline of -10.06%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 19, 2020 when Maxim Group began covering the stock and recommended ‘”a Buy”‘ rating along with a $8 price target.
